Dr. Glynn Wilson | Chief Executive Officer
Glynn brings an extensive background of success in corporate management and product development with tenures in both multinational and start-up biotech organizations. He was formerly Head of Drug Delivery at SmithKline Beecham Pharmaceuticals, Research Area Head in Advanced Drug Delivery at Ciba-Geigy Pharmaceuticals, and Founder, CEO, and Chairman of TapImmune Inc. for 12 years which became Marker Therapeutics through a merger. At TapImmune he licensed cancer vaccine technology platforms and established the clinical pipeline.
Brian John | Chief Investment Officer
For the past 20 years, Brian has been an investor and global advisor to companies around the globe. He is the Founder of a highly successful financial consulting firm specializing in assisting emerging growth companies primarily in the sub- $100 million space and has worked with hundreds of companies in dozens of countries over the last 25 years. He also serves on the board of directors of The Learning Center at the Els Center of Excellence–a school for children with autism in Jupiter, Florida.
Andrew Simmons | Director
Andrew was previously the Founder and Partner of American Yacht Group, one of the United States Largest New Yacht Dealerships producing over $100 Million Dollars in sales Annually since inception in 2019. Andrew’s Success at American Yacht Group Led to over a 50% Growth in Annual Sales for HCB Yachts. Most recently Andrew shifted and was promoted to President of Sales for HCB Yachts Globally. Mr. Simmons was appointed to the board because of his demonstrated ability to drive growth in competitive markets through innovative sales strategies and strong leadership. His experience in scaling businesses bring a valuable commercial perspective that will support the company’s expansion efforts and revenue growth initiatives.